Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00098514 · ClinicalTrials.gov registry record · Phase 1
Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT00098514 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 53 participants.
The verdict
NCT00098514, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying side effects, best way to give, and best dose of talotrexin in treating patients with advanced or recurrent solid tumors.
Interventions
- DRUG talotrexin ammonium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2003-12 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00098514
The ClinicalTrials.gov registry entry for NCT00098514 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which talotrexin ammonium is the first listed.
NCT00098514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00098514 about?
NCT00098514 is a clinical study titled "Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors". RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying side effects, best way to give, and best dose of talotrexin in treating patient...
What is the current status of trial NCT00098514?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2003-12. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00098514?
The interventions under investigation include: talotrexin ammonium (DRUG).
Who is sponsoring clinical trial NCT00098514?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.